U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07883161) titled 'Targeted Nutritional Intervention (HMB, Arginine, Glutamine) in Patients With Pancreatic Cancer' on Oct. 07.
Brief Summary: Pancreatic ductal adenocarcinoma (PDAC) is frequently associated with cancer cachexia, a condition characterized by progressive loss of skeletal muscle mass and strength driven by systemic inflammation. Recent evidence suggests that chemotherapy and tumor-related inflammation disrupt the gut-muscle axis, leading to increased intestinal permeability and bacterial imbalance (dysbiosis), which further worsen muscle loss.
The purpose of this pilot study is to evaluate whether an early, targeted nutritional supplem...